U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H12ClF3N4O4.C7H17NO5
Molecular Weight 635.975
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DELAFLOXACIN MEGLUMINE

SMILES

c1c2c(c(c(c1F)N3CC(C3)O)Cl)n(cc(c2=O)C(=O)O)-c4c(cc(c(=N)[nH]4)F)F.CNC[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(CO)O)O)O)O

InChI

InChIKey=AHJGUEMIZPMAMR-WZTVWXICSA-N
InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

HIDE SMILES / InChI

Molecular Formula C7H17NO5
Molecular Weight 195.2139
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C18H12ClF3N4O4
Molecular Weight 440.7611
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/history/baxdela.html http://www.malinplc.com/wp-content/uploads/2015/10/Melinta-Therapeutics-Presents-Complete-Delafloxacin-Results-09.10.15.pdf

Delafloxacin (CAS registry number 189279-58-1) was described as WQ-3034 by Wakunaga Pharmaceutical Co., Ltd., Osaka & Hiroshima, Japan. It was first licensed in 1999 to Abbott Park, IL, and further developed as ABT-492. Delafloxacin (Baxdela), a fluoroquinolone antibiotic, is currently being developed by Melinta Therapeutics. It is a novel investigational fluoroquinolone in development for the treatment of uncomplicated gonorrhea, and acute bacterial skin and skin structure infections. Delafloxacin shows MICs remarkably low against Gram-positive organisms and anaerobes and similar to those of ciprofloxacin against Gram-negative bacteria. It remains active against most fluoroquinolone-resistant strains, except enterococci. Its potency is further increased in acidic environments (found in many infection sites). Delafloxacin is active on staphylococci growing intracellularly or in biofilms. Delafloxacin is a dual-targeting fluoroquinolone, capable of forming cleavable complexes with DNA and topoisomerase IV or DNA gyrase and of inhibiting the activity of these enzymes in both Gram-positive and Gram-negative bacteria. On Oct 24, 2016, Melinta Therapeutics Submitted Baxdela New Drug Application for hospital-treated skin infections.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BAXDELA

Approved Use

BAXDELA is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.2)

Launch Date

1.49774402E12
Curative
BAXDELA

Approved Use

BAXDELA is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.2)

Launch Date

1.49774402E12
Curative
BAXDELA

Approved Use

BAXDELA is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. (1.1) To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (1.2)

Launch Date

1.49774402E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.94 μg/mL
300 mg single, intravenous
dose: 300 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DELAFLOXACIN MEGLUMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7.17 μg/mL
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DELAFLOXACIN MEGLUMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
9.29 μg/mL
300 mg 2 times / day steady-state, intravenous
dose: 300 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DELAFLOXACIN MEGLUMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7.45 μg/mL
450 mg 2 times / day steady-state, oral
dose: 450 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DELAFLOXACIN MEGLUMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
21.8 μg × h/mL
300 mg single, intravenous
dose: 300 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DELAFLOXACIN MEGLUMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
22.7 μg × h/mL
450 mg single, oral
dose: 450 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DELAFLOXACIN MEGLUMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
23.4 μg × h/mL
300 mg 2 times / day steady-state, intravenous
dose: 300 mg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DELAFLOXACIN MEGLUMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
30.8 μg × h/mL
450 mg 2 times / day steady-state, oral
dose: 450 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DELAFLOXACIN MEGLUMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.7 h
300 mg single, intravenous
dose: 300 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DELAFLOXACIN MEGLUMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
16%
300 mg single, intravenous
dose: 300 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DELAFLOXACIN MEGLUMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Other AEs: Nausea, Gastrointestinal disorders...
Other AEs:
Nausea (50%)
Gastrointestinal disorders (87.5%)
Vomiting (75%)
Diarrhea (25%)
Retching (12.5%)
Nervous system disorders (12.5%)
Dizziness (12.5%)
Feeling hot (12.5%)
Respiratory, thoracic and mediastinal disorders (12.5%)
Rhinorrhea (12.5%)
Skin and subcutaneous tissue disorders (12.5%)
Pruritus
Sources:
300 mg 2 times / day multiple, intravenous
Recommended
Dose: 300 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Age Group: adult
Sources:
Disc. AE: Tendinitis, Tendon rupture...
AEs leading to
discontinuation/dose reduction:
Tendinitis (serious)
Tendon rupture (serious)
Peripheral neuropathy (serious)
Myasthenia gravis (serious)
Sources:
300 mg 2 times / day multiple, intravenous
Recommended
Dose: 300 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 2 times / day
Sources: Page: p. 163
unhealthy
n = 741
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Population Size: 741
Sources: Page: p. 163
Disc. AE: Hypersensitivity...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity (0.1%)
Sources: Page: p. 163
300 |450 mg|mg 2 times / day multiple, intravenous|oral (complex)
Recommended
Dose: 300 |450 mg|mg, 2 times / day
Route: intravenous|oral
Route: multiple
Dose: 300 |450 mg|mg, 2 times / day
Sources: Page: p. 163
unhealthy
n = 741
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Population Size: 741
Sources: Page: p. 163
Disc. AE: Vomiting, Hypersensitivity...
AEs leading to
discontinuation/dose reduction:
Vomiting (0.1%)
Hypersensitivity (0.1%)
Urticaria (0.3%)
Dermatitis allergic (0.1%)
Sources: Page: p. 163
AEs

AEs

AESignificanceDosePopulation
Pruritus
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Dizziness 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Feeling hot 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Nervous system disorders 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Respiratory, thoracic and mediastinal disorders 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Retching 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Rhinorrhea 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Skin and subcutaneous tissue disorders 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Diarrhea 25%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Nausea 50%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Vomiting 75%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Gastrointestinal disorders 87.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
healthy, 19- 64 years
n = 8
Health Status: healthy
Age Group: 19- 64 years
Sex: M+F
Population Size: 8
Sources:
Myasthenia gravis serious
Disc. AE
300 mg 2 times / day multiple, intravenous
Recommended
Dose: 300 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Age Group: adult
Sources:
Peripheral neuropathy serious
Disc. AE
300 mg 2 times / day multiple, intravenous
Recommended
Dose: 300 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Age Group: adult
Sources:
Tendinitis serious
Disc. AE
300 mg 2 times / day multiple, intravenous
Recommended
Dose: 300 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Age Group: adult
Sources:
Tendon rupture serious
Disc. AE
300 mg 2 times / day multiple, intravenous
Recommended
Dose: 300 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Age Group: adult
Sources:
Hypersensitivity 0.1%
Disc. AE
300 mg 2 times / day multiple, intravenous
Recommended
Dose: 300 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 2 times / day
Sources: Page: p. 163
unhealthy
n = 741
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Population Size: 741
Sources: Page: p. 163
Dermatitis allergic 0.1%
Disc. AE
300 |450 mg|mg 2 times / day multiple, intravenous|oral (complex)
Recommended
Dose: 300 |450 mg|mg, 2 times / day
Route: intravenous|oral
Route: multiple
Dose: 300 |450 mg|mg, 2 times / day
Sources: Page: p. 163
unhealthy
n = 741
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Population Size: 741
Sources: Page: p. 163
Hypersensitivity 0.1%
Disc. AE
300 |450 mg|mg 2 times / day multiple, intravenous|oral (complex)
Recommended
Dose: 300 |450 mg|mg, 2 times / day
Route: intravenous|oral
Route: multiple
Dose: 300 |450 mg|mg, 2 times / day
Sources: Page: p. 163
unhealthy
n = 741
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Population Size: 741
Sources: Page: p. 163
Vomiting 0.1%
Disc. AE
300 |450 mg|mg 2 times / day multiple, intravenous|oral (complex)
Recommended
Dose: 300 |450 mg|mg, 2 times / day
Route: intravenous|oral
Route: multiple
Dose: 300 |450 mg|mg, 2 times / day
Sources: Page: p. 163
unhealthy
n = 741
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Population Size: 741
Sources: Page: p. 163
Urticaria 0.3%
Disc. AE
300 |450 mg|mg 2 times / day multiple, intravenous|oral (complex)
Recommended
Dose: 300 |450 mg|mg, 2 times / day
Route: intravenous|oral
Route: multiple
Dose: 300 |450 mg|mg, 2 times / day
Sources: Page: p. 163
unhealthy
n = 741
Health Status: unhealthy
Condition: acute bacterial skin and skin structure infections
Population Size: 741
Sources: Page: p. 163
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
yes
no (co-administration study)
Comment: An in vivo DDI study (Study ML-3341-118) of multiple oral doses of delafloxacin (450 mg Q12h) on a single oral dose of midazolam (5 mg) demonstrated no impact on midazolam PK, and minimal impact on 1-hydroxymidazolam PK
Page: 16.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
yes
yes
yes
no (co-administration study)
Comment: Delafloxacin AUC0-24 values from patients who received P-gp/BCRP inhibitors along with delafloxacin are overlayed with the values from patients who received no P-gp/BCRP inhibitors.
Page: 37.0
yes
no (co-administration study)
Comment: Delafloxacin AUC0-24 values from patients who received P-gp/BCRP inhibitors along with delafloxacin are overlayed with the values from patients who received no P-gp/BCRP inhibitors.
Page: 37.0
yes
yes (pharmacogenomic study)
Comment: The Cmin data from Study M00-224 seems significantly correlated with UGT2B15*2 genotype. Due to the small sample size (N=27), Applicant concluded that further confirmation is required to elucidate the role of UGT2B15.
Page: 15.0
Tox targets

Tox targets

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
2000 Feb
New antibiotics for antibiotic-resistant bacteria.
2009 May 28
Methicillin-resistant Staphylococcus aureus: a pervasive pathogen highlights the need for new antimicrobial development.
2010 Dec
Patents

Sample Use Guides

900mg orally (2 x 450 mg tablets) administered once
Route of Administration: Oral
Delafloxacin demonstrated potent in vitro activity against this set of Staphylococcus aureus (MRSA) isolates, with MICs of 0.008-1 mg/L and an MIC(50) and MIC(90) of 0.03 and 0.5 mg/L, respectively.
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:30:15 UTC 2021
Edited
by admin
on Sat Jun 26 16:30:15 UTC 2021
Record UNII
N7V53U4U4T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DELAFLOXACIN MEGLUMINE
USAN   WHO-DD  
USAN  
Official Name English
D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, 1-(6-AMINO-3,5-DIFLUORO-2-PYRIDINYL)-8-CHLORO-6-FLUORO-1,4-DIHYDRO-7-(3-HYDROXY-1-AZETIDINYL)-4-OXO-3-QUINOLINECARBOXYLATE (SALT)
Common Name English
1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL 1-(6-AMINO-3,5-DIFLUOROPYRIDIN-2-YL)-8-CHLORO-6-FLUORO-7-(3-HYDROXYAZETIDIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLATE (SALT)
Common Name English
DELAFLOXACIN MEGLUMINE [MI]
Common Name English
RX-3341 MEGLUMINE
Common Name English
ABT-492 MEGLUMINE
Code English
DELAFLOXACIN MEGLUMINE [USAN]
Common Name English
DELAFLOXACIN MEGLUMINE [ORANGE BOOK]
Common Name English
DELAFLOXACIN MEGLUMINE [WHO-DD]
Common Name English
WQ-3034 MEGLUMINE
Common Name English
Code System Code Type Description
PUBCHEM
11578213
Created by admin on Sat Jun 26 16:30:16 UTC 2021 , Edited by admin on Sat Jun 26 16:30:16 UTC 2021
PRIMARY
CAS
352458-37-8
Created by admin on Sat Jun 26 16:30:16 UTC 2021 , Edited by admin on Sat Jun 26 16:30:16 UTC 2021
PRIMARY
MERCK INDEX
M12032
Created by admin on Sat Jun 26 16:30:16 UTC 2021 , Edited by admin on Sat Jun 26 16:30:16 UTC 2021
PRIMARY
EPA CompTox
352458-37-8
Created by admin on Sat Jun 26 16:30:16 UTC 2021 , Edited by admin on Sat Jun 26 16:30:16 UTC 2021
PRIMARY
RXCUI
1927662
Created by admin on Sat Jun 26 16:30:16 UTC 2021 , Edited by admin on Sat Jun 26 16:30:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL2105637
Created by admin on Sat Jun 26 16:30:16 UTC 2021 , Edited by admin on Sat Jun 26 16:30:16 UTC 2021
PRIMARY
NCI_THESAURUS
C174746
Created by admin on Sat Jun 26 16:30:16 UTC 2021 , Edited by admin on Sat Jun 26 16:30:16 UTC 2021
PRIMARY
DRUG BANK
DBSALT002486
Created by admin on Sat Jun 26 16:30:16 UTC 2021 , Edited by admin on Sat Jun 26 16:30:16 UTC 2021
PRIMARY
FDA UNII
N7V53U4U4T
Created by admin on Sat Jun 26 16:30:16 UTC 2021 , Edited by admin on Sat Jun 26 16:30:16 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
SOLUBILITY CHEMICAL FINAL pH
CHEMICAL
SOLVENT
CHEMICAL
TEMPERATURE
PHYSICAL
SOLUBILITY CHEMICAL TEMPERATURE
PHYSICAL
SOLVENT
CHEMICAL
FINAL pH
CHEMICAL
SOLUBILITY CHEMICAL FINAL pH
PHYSICAL
TEMPERATURE
PHYSICAL
SOLVENT
PHYSICAL
SOLUBILITY CHEMICAL FINAL pH
CHEMICAL
SOLVENT
CHEMICAL
TEMPERATURE
PHYSICAL
SOLUBILITY CHEMICAL TEMPERATURE
PHYSICAL
FINAL pH
CHEMICAL
SOLVENT
CHEMICAL